CA3045959A1 - Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors - Google Patents

Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors Download PDF

Info

Publication number
CA3045959A1
CA3045959A1 CA3045959A CA3045959A CA3045959A1 CA 3045959 A1 CA3045959 A1 CA 3045959A1 CA 3045959 A CA3045959 A CA 3045959A CA 3045959 A CA3045959 A CA 3045959A CA 3045959 A1 CA3045959 A1 CA 3045959A1
Authority
CA
Canada
Prior art keywords
compound
6alkyl
chloro
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3045959A
Other languages
English (en)
French (fr)
Inventor
Jing Li
Haibo Zhao
Zhiwei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CA3045959A1 publication Critical patent/CA3045959A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3045959A 2016-12-07 2017-12-07 Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors Pending CA3045959A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016108897 2016-12-07
CNPCT/CN2016/108897 2016-12-07
PCT/CN2017/114970 WO2018103688A1 (en) 2016-12-07 2017-12-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Publications (1)

Publication Number Publication Date
CA3045959A1 true CA3045959A1 (en) 2018-06-14

Family

ID=62491736

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3045959A Pending CA3045959A1 (en) 2016-12-07 2017-12-07 Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors

Country Status (16)

Country Link
US (2) US11136323B2 (https=)
EP (1) EP3551630A4 (https=)
JP (2) JP7064495B2 (https=)
KR (1) KR20190091339A (https=)
CN (2) CN110267959B (https=)
AU (2) AU2017372377B2 (https=)
BR (1) BR112019011847A2 (https=)
CA (1) CA3045959A1 (https=)
EA (1) EA201991355A1 (https=)
IL (2) IL266986B (https=)
MX (1) MX394882B (https=)
NZ (1) NZ754944A (https=)
SG (1) SG10201912192RA (https=)
TW (2) TW202233190A (https=)
WO (1) WO2018103688A1 (https=)
ZA (1) ZA201903286B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233190A (zh) * 2016-12-07 2022-09-01 英屬開曼群島商百濟神州有限公司 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
JP2023503230A (ja) * 2019-11-21 2023-01-27 ベイジーン リミテッド Pi3キナーゼデルタ阻害剤との組合せで抗ox40抗体を用いる癌治療の方法
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
JP2024521763A (ja) * 2021-05-27 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー Pi3kデルタ阻害剤の塩、その結晶形態、調製方法、及び使用
KR20240060647A (ko) * 2021-09-14 2024-05-08 베이진 엘티디 Btk 저해제와 pi3 키나제 저해제의 조합물을 이용하는 암 치료 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100872204B1 (ko) 2003-10-15 2008-12-09 오에스아이 파마슈티컬스, 인코포레이티드 이미다조피라진 티로신 키나제 억제제
SG175195A1 (en) 2009-04-16 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
CA2825028A1 (en) * 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
EP2802586B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
SG11201509842SA (en) 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20210317140A1 (en) * 2013-10-18 2021-10-14 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
MA40596B1 (fr) 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
TW202233190A (zh) * 2016-12-07 2022-09-01 英屬開曼群島商百濟神州有限公司 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑

Also Published As

Publication number Publication date
US20220098202A1 (en) 2022-03-31
TW202233190A (zh) 2022-09-01
EA201991355A1 (ru) 2019-11-29
US20190367523A1 (en) 2019-12-05
TWI762534B (zh) 2022-05-01
EP3551630A4 (en) 2020-07-15
EP3551630A1 (en) 2019-10-16
AU2022203737A1 (en) 2022-06-23
CN114805366A (zh) 2022-07-29
CN110267959B (zh) 2022-05-27
IL290419B2 (en) 2023-02-01
US11136323B2 (en) 2021-10-05
KR20190091339A (ko) 2019-08-05
WO2018103688A1 (en) 2018-06-14
IL266986A (en) 2019-07-31
ZA201903286B (en) 2021-01-27
JP2022090051A (ja) 2022-06-16
SG10201912192RA (en) 2020-02-27
BR112019011847A2 (pt) 2019-10-29
MX394882B (es) 2025-03-24
IL290419A (en) 2022-04-01
IL290419B (en) 2022-10-01
US11725012B2 (en) 2023-08-15
MX2019006612A (es) 2019-08-01
IL266986B (en) 2022-03-01
CN110267959A (zh) 2019-09-20
AU2017372377A1 (en) 2019-07-18
JP7064495B2 (ja) 2022-05-10
NZ754944A (en) 2023-02-24
AU2017372377B2 (en) 2022-03-03
JP2020500909A (ja) 2020-01-16
TW201833113A (zh) 2018-09-16

Similar Documents

Publication Publication Date Title
US11725012B2 (en) Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
US11905294B2 (en) Imidazo[1,5-a]pyrazine derivatives as PI3Kδ inhibitors
JP7551607B2 (ja) アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体
CN111592541B (zh) 大环类激酶抑制剂及其用途
WO2020048409A1 (en) 1,5-NAPHTHYRIDIN-4(1H)-ONE DERIVATIVES AS PI3Kbeta INHIBITORS
EA040746B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kδ
HK40088309A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
EA040339B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3Kδ
HK40029822B (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
HK40029822A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220729